Triangle-based Metabolon is adding to its geographic footprint through the acquisition of a German company that also focuses on metabolomics.
Becoming part of Metabolon is Metabolomic Discoveries GmbH, which is based near Berlin.
The deal comes eight months after Metabolon closed on $15 million in new funding and began expanding its management team.
Metabolon, which launched in 2000, defines metabolomics as the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
“The acquisition of Metabolomic Discoveries builds on our vision to bring the value of metabolomics to regions around the globe as we continue to realize the promise of this unique and powerful technology,” said Metabolon CEO John Ryals in a statement.
“This achievement acts as yet another proof point of our expansion and leadership in the metabolomics space, delivering new services and clinical products that improve health. The addition of Metabolomic Discoveries furthers our global expansion strategy and will provide us with greater access to the European market as we continue to innovate and grow.”
Financial terms were not disclosed.
Metabolon also has struck collaboation deals to expand its research capabilities in China and in the Middle East.
The managing director and cofounder of the German firm, Nicolas Schaurer, will become part of Metabolon’s executive team.
“This is a great opportunity to combine our metabolomics expertise and approaches,” Schauer said. “Joining the leading metabolomics and biomarker company will enable us to offer new services and precision medicine products to a broader group of researchers and clinicians. I look forward to accelerating the metabolomics market in Europe with Metabolon.”